Autonomic dysreflexia: Current pharmacologic management
PM&R · 2023
DOI: 10.1002/pmrj.13051 ↗Kurz gefasst
Fachartikel in der Zeitschrift PM&R, 2023. Verfasst von Ryan Solinsky. Beteiligte Einrichtung: Spaulding Rehabilitation Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Autonomic Dysreflexia, Spinal Cord Injuries. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Background
Autonomic dysreflexia (AD) is a frequent complication of spinal cord injury (SCI), though current clinical practice patterns for medication management of this condition are unknown. Correspondingly, it is unclear if national differences in practice patterns exist.
Objective
To determine trends in current pharmacologic management of AD throughout the Americas.
Design
International survey of current physician practice patterns.
Setting
Academic medical center.
Participants
Sixty physicians managing patients with SCI and prescribing medications to manage AD.
Interventions
Not applicable. Main Outcome Measures Presence of a formal pharmacologic AD management protocol, first‐ and second‐line medications, patient characteristics influencing pharmacologic management.
Results
The majority of physicians (69%) had a formal AD management protocol for inpatient care, with nitroglycerin ointment (82%) being the most common first‐line medication. Strong national differences existed regarding the use of nitroglycerin ointment, with 98% of U.S.‐based physicians using this as first‐line medication and 0% of physicians in Canada or Latin America using this due to recent lack of medication availability. Only 67% of physicians had a preferred second‐line medication, with preferences split between hydralazine (48%) and nifedipine (28%). A systolic blood pressure threshold for pharmacologic management was used by 56% of physicians, wheres 26% considered neurological level of injury in decisions to use medications for AD. Heart rate was used by only 5% of physicians in their decision to manage AD with medications.
Conclusions
As of 2023, U.S.‐based physicians caring for individuals with SCI largely have formal inpatient protocols in place for medication management of AD, with nearly all relying on nitroglycerin ointment as their first‐line medication. In areas outside of the United States where nitroglycerin ointment is unavailable, pharmacologic practice patterns significantly differ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Spaulding Rehabilitation Hospital, Boston, Massachusetts, USA.
- Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, USA.
ORCID-Profile: Ryan Solinsky
Förderung
- NICHD NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Solinsky, R. (2023). Autonomic dysreflexia: Current pharmacologic management. PM&R. https://doi.org/10.1002/pmrj.13051
Vancouver
Solinsky R. Autonomic dysreflexia: Current pharmacologic management. PM&R. 2023. doi:10.1002/pmrj.13051
BibTeX
@article{Solinsky2023,
author = {Solinsky, Ryan},
title = {Autonomic dysreflexia: Current pharmacologic management},
journal = {PM&R},
year = {2023},
doi = {10.1002/pmrj.13051}
}
EUVIMED